• Monomethyl Auristatin E: Protocols and Precision in ADC Payl

  2026-05-21

  Monomethyl auristatin E (MMAE) empowers targeted cancer therapy with unrivaled potency as an ADC payload. This guide covers practical workflows, parameterized protocols, and troubleshooting strategies to maximize MMAE’s impact in preclinical and translational settings.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC Cells

  2026-05-21

  This study establishes that HDAC inhibition can reverse Epstein-Barr virus (EBV)-driven dedifferentiation in nasopharyngeal carcinoma (NPC), highlighting a new epigenetic mechanism for targeting cancer cell plasticity. The findings support the potential of differentiation therapy in solid tumors and set a precedent for using chromatin-modifying strategies to overcome therapeutic resistance.

• Advancing In Vitro Evaluation of Cancer Drug Responses

  2026-05-20

  Schwartz's dissertation introduces a rigorous framework for distinguishing between proliferative arrest and cell death in anti-cancer drug studies. This approach enhances the precision of in vitro drug evaluation and informs the interpretation of targeted inhibitors like Cediranib (AZD2171) in cancer research.

• Phosbind Biotin LC: Sequence-Independent Phosphorylation Det

  2026-05-20

  Phosbind Biotin LC addresses the challenge of detecting phosphorylated proteins on PVDF membranes when phospho-specific antibodies are unavailable or limited by sequence context. It is optimized for Western Blot applications but is not suitable for aqueous-only protocols or scenarios needing long-term working solution storage.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Fluorescent Precisio

  2026-05-19

  Explore how the Cy3 Goat Anti-Human IgG (H+L) Antibody elevates sensitivity and specificity in immunofluorescence assays. This article reveals unique cross-domain insights for translational virology and advanced immunoassay workflows.

• In Vitro Drug Response Metrics: Improving Cancer Research Pr

  2026-05-19

  Schwartz's dissertation introduces a refined in vitro methodology that distinguishes between cancer drug-induced proliferative arrest and cell death, highlighting the importance of separate quantitative metrics. These insights support more accurate evaluation of compounds like Cediranib (AZD2171), with broad ramifications for translational oncology workflows.

• MK-4827 (Niraparib): Advanced DNA Damage Repair Inhibition W

  2026-05-18

  MK-4827 (Niraparib) empowers researchers to dissect DNA repair mechanisms and develop innovative strategies for overcoming chemoresistance in BRCA-mutant and proficient cancer models. Leveraging its nanomolar potency and robust selectivity, this PARP-1/-2 inhibitor from APExBIO is a cornerstone for both monotherapy and combination research approaches.

• Cdc42 Inhibition Mitigates Kidney Fibrosis via β-catenin Pat

  2026-05-18

  This study identifies Cdc42 as a direct molecular target in kidney fibrosis and demonstrates that the natural product daphnepedunin A (DA) suppresses fibrotic progression by disrupting Cdc42-mediated GSK-3β/β-catenin signaling. The findings provide a mechanistic rationale for selective Cdc42 inhibitor use in fibrotic disease research and highlight the translational potential of targeting this pathway.

• CPI-613: Applied Workflows for Tumor Cell Metabolism Studies

  2026-05-17

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) redefines mitochondrial metabolism studies by enabling precise, reproducible disruption of PDH and KGDH in cancer models. This guide delivers workflow enhancements, troubleshooting tactics, and actionable insights for acute myeloid leukemia, NSCLC, and emerging cuproptosis assays.

• BV6 IAP Antagonist: Precision Apoptosis Induction in Cancer

  2026-05-16

  BV6, a potent IAP antagonist from APExBIO, enables robust, selective apoptosis induction—empowering cancer and endometriosis research with reproducibility and translational relevance. This article provides stepwise protocols, troubleshooting insights, and actionable guidance for maximizing BV6 performance in cell-based and in vivo models.

• Nerve-Dependent HDAC1 Regulation Governs Axolotl Limb Regene

  2026-05-15

  This study reveals that limb regeneration in axolotls critically depends on nerve-mediated upregulation of histone deacetylase 1 (HDAC1), with HDAC inhibition markedly impairing blastema formation and regrowth. The findings highlight a precise epigenetic control mechanism linking neural signals to regenerative capacity, with implications for designing targeted HDAC modulation protocols.

• JNJ-10198409: Precision Platelet-Derived Growth Factor Recep

  2026-05-15

  JNJ-10198409, from APExBIO, offers unmatched specificity and potency for researchers targeting PDGF-driven tumor growth and fibrotic processes. Its nanomolar efficacy and robust antiangiogenic action enable advanced mechanistic studies and translational workflow optimization.

• Peptidisc-Assisted Clustering for Multimeric Nanobody Assemb

  2026-05-14

  Chen and Duong van Hoa introduce a peptidisc-based approach for creating stable, multimeric, and multispecific nanobody complexes, termed polybodies. This strategy leverages hydrophobic clustering to enhance nanobody assembly, offering a versatile alternative to classical protein multimerization methods with broad implications in protein engineering.

• EdU Flow Cytometry Assay Kits (Cy3): Precision for S-Phase D

  2026-05-14

  Leverage EdU Flow Cytometry Assay Kits (Cy3) for sensitive, multiplexable, and denaturation-free cell proliferation analysis. This guide distills best practices, advanced applications, and troubleshooting strategies to ensure reproducible results in DNA replication measurement and genotoxicity testing.

• Caspase-4 Colorimetric Assay Kit: Precision in Pyroptosis an

  2026-05-13

  Explore how the Caspase-4 Colorimetric Assay Kit enables rigorous, quantitative detection of inflammatory and pyroptotic responses. This article reveals new scientific insights and practical protocols for researchers seeking advanced applications in caspase signaling pathway studies.

16583 records 1/1106 page Next 12345 下5页 Last page